+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Cell Reprogramming Market - Global Forecast 2025-2030- Product Image
Cell Reprogramming Market - Global Forecast 2025-2030- Product Image
Sale

Cell Reprogramming Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 193 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6010765
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The cell reprogramming market is rapidly evolving as a critical segment within contemporary biotechnology, with sectoral growth shaped by advancements in cell manipulation technologies, changes in trade policy, and varied regional investment climates. Senior executives seeking to optimize resource allocation and competitive positioning will find actionable insights for navigating shifting market dynamics and innovation trends in this report.

Market Snapshot: Cell Reprogramming Market 2024–2030

The cell reprogramming market grew from USD 413.88 million in 2024 to USD 458.87 million in 2025 and is forecast to continue its trajectory at a CAGR of 10.67%, reaching USD 760.75 million by 2030. This growth is due to expanding applications in regenerative medicine, improved differentiation protocols, and integration of novel engineering platforms. Robust demand is seen across research institutions, pharmaceutical firms, and emerging biotech companies, driven by enhanced efficiency and reproducibility in cell reprogramming processes. Market expansion is further supported by investments in new technology platforms that enable precise cell fate determination and support disease modeling and drug discovery programs.

Scope & Segmentation of the Cell Reprogramming Market

  • Technology: Direct reprogramming protocols and induced pluripotent stem cell (iPSC) methodologies are core segments, each offering unique workflows and safety profiles.
  • Cell Type: Cardiomyocytes, neurons, and pancreatic beta cells constitute the primary cell types addressed, representing major disease modeling and therapeutic targets.
  • Application: Market applications include cell therapy, disease modeling, and drug discovery, underpinned by enhanced cellular fidelity and improved response prediction capabilities.
  • Reprogramming Methods: Small molecule approaches such as DNA methyltransferase inhibitors and histone deacetylase inhibitors, along with gene-based methods using viral and non-viral vectors, electroporation, and lipid-based transfection technologies, are actively deployed.
  • End User: Key stakeholders comprise academic institutions, biotech and pharmaceutical companies, and contract research organizations, each with distinct project goals and resource needs.
  • Regional Coverage: Geographic focus includes the Americas (notably United States—California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio—plus Canada, Mexico, Brazil, Argentina), Europe, Middle East, and Africa (including the United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland), and Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan).
  • Companies Analyzed: Key players profiled comprise Thermo Fisher Scientific Inc., Merck KGaA, Lonza Group AG, Danaher Corporation, STEMCELL Technologies Inc., Takara Bio Inc., FUJIFILM Cellular Dynamics Inc., Miltenyi Biotec GmbH, Bio-Techne Corporation, and ReproCELL, Inc.

Key Takeaways and Strategic Insights

  • Direct reprogramming is gaining preference for its streamlined workflow and reduced tumorigenicity risk compared to traditional pluripotency-based approaches. This enhances use in preclinical safety studies and accelerates therapeutic development.
  • Epigenetic modulation and small molecule cocktails are enabling researchers to fine-tune cell fate with higher specificity, supporting expansion into complex disease models and hard-to-treat conditions.
  • Integration of high-throughput automation and digital analytics is standardizing protocols, supporting reproducibility, and facilitating modeling of cell reprogramming kinetics to optimize outcomes.
  • Collaboration across academia and industry is improving protocol optimization, regulatory navigation, and knowledge exchange, fostering a more connected innovation ecosystem.
  • Regional policy incentives and public-private partnerships, especially in Asia-Pacific and the Americas, are accelerating infrastructure development while supporting scalable manufacturing and clinical translation.
  • Engagement with supply chain diversification and responsive inventory management is proving vital as the sector adapts to shifting regulatory and economic landscapes.

Tariff Impact: Navigating U.S. Trade Policy Shifts

Recent U.S. tariffs on imported reagents and laboratory equipment have elevated operational costs for cell reprogramming labs and contract service providers. This has prompted organizations to pursue alternative sourcing strategies, strengthen local manufacturing partnerships, and implement strategic stockpiling to reduce vulnerabilities. Multi-stakeholder collaborations, both academic and industrial, now feature shared inventory and cost-sharing models to limit exposure. Engagement with policymakers continues as the sector advocates for research-driven tariff classifications and streamlined customs procedures.

Methodology & Data Sources

This analysis uses a rigorous mixed-methods approach, beginning with in-depth reviews of scientific publications, patents, and regulatory documents. Structured interviews and expert panels provide qualitative insights, while quantitative metrics and adoption patterns are cross-checked against supplier reports. Statistical correlation and peer validation ensure credible and actionable findings.

Why This Report Matters

  • Supports senior decision-makers with actionable frameworks to guide investments, partnerships, and supply management in a changing cell reprogramming landscape.
  • Enables effective benchmarking of technology adoption, therapeutic potential, and regional readiness, ensuring resource allocation aligns with the latest advancements.
  • Offers clear recommendations for maximizing competitive advantage through collaborative research, regulatory engagement, and next-generation technology integration.

Conclusion

The cell reprogramming market is advancing through collaborative innovation, proactive policy adaptation, and targeted investment strategies. Decision-makers can leverage this analysis to position their organizations at the forefront of biotechnological progress and accelerate the application of reprogramming breakthroughs to research and clinical challenges.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Integration of AI and machine learning algorithms to enhance iPSC reprogramming efficiency and predict differentiation outcomes
5.2. Development of non-integrating vector systems for safer in vivo cell reprogramming therapies with reduced genomic risk
5.3. Adoption of automated high-throughput screening platforms for optimizing small molecule cocktails in direct cell fate conversion
5.4. Expansion of clinical-grade xeno-free culture media formulations to support scalable manufacturing of reprogrammed cell therapies
5.5. Emergence of CRISPR-based epigenome editing techniques to facilitate lineage-specific reprogramming without genome modification
5.6. Partnerships between biotech startups and pharmaceutical companies to accelerate translational pipelines for reprogrammed cell products
5.7. Implementation of real-time single-cell transcriptomic monitoring to improve quality control during reprogramming processes
5.8. Regulatory advancements and standardized guidelines for GMP-compliant production of cell reprogrammed therapeutic candidates
5.9. Growing interest in in vivo reprogramming approaches for tissue regeneration in neurodegenerative and cardiovascular disease models
5.10. Investment in organoid-based disease models derived from patient-specific reprogrammed cells for precision drug screening
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Cell Reprogramming Market, by Technology
8.1. Introduction
8.2. Direct Reprogramming
8.3. Ipsc
9. Cell Reprogramming Market, by Cell Type
9.1. Introduction
9.2. Cardiomyocytes
9.3. Neurons
9.4. Pancreatic Beta Cells
10. Cell Reprogramming Market, by Application
10.1. Introduction
10.2. Cell Therapy
10.3. Disease Modeling
10.4. Drug Discovery
11. Cell Reprogramming Market, by Reprogramming Method
11.1. Introduction
11.2. Small Molecules
11.2.1. Dna Methyltransferase Inhibitors
11.2.2. Histone Deacetylase Inhibitors
11.3. Transduction
11.3.1. Non-Viral Vector
11.3.2. Viral Vector
11.4. Transfection
11.4.1. Electroporation
11.4.2. Lipid Based
12. Cell Reprogramming Market, by End User
12.1. Introduction
12.2. Academic Institutions
12.3. Biotech Pharma
12.4. Cros
13. Americas Cell Reprogramming Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Cell Reprogramming Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Cell Reprogramming Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Thermo Fisher Scientific Inc.
16.3.2. Merck KGaA
16.3.3. Lonza Group AG
16.3.4. Danaher Corporation
16.3.5. STEMCELL Technologies Inc.
16.3.6. Takara Bio Inc.
16.3.7. FUJIFILM Cellular Dynamics Inc.
16.3.8. Miltenyi Biotec GmbH
16.3.9. Bio-Techne Corporation
16.3.10. ReproCELL, Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. CELL REPROGRAMMING MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL CELL REPROGRAMMING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 6. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY CELL TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY CELL TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY REPROGRAMMING METHOD, 2024 VS 2030 (%)
FIGURE 12. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY REPROGRAMMING METHOD, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS CELL REPROGRAMMING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS CELL REPROGRAMMING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES CELL REPROGRAMMING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES CELL REPROGRAMMING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CELL REPROGRAMMING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CELL REPROGRAMMING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC CELL REPROGRAMMING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC CELL REPROGRAMMING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. CELL REPROGRAMMING MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. CELL REPROGRAMMING MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. CELL REPROGRAMMING MARKET: RESEARCHAI
FIGURE 26. CELL REPROGRAMMING MARKET: RESEARCHSTATISTICS
FIGURE 27. CELL REPROGRAMMING MARKET: RESEARCHCONTACTS
FIGURE 28. CELL REPROGRAMMING MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. CELL REPROGRAMMING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL CELL REPROGRAMMING MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL CELL REPROGRAMMING MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY DIRECT REPROGRAMMING, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY DIRECT REPROGRAMMING, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY IPSC, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY IPSC, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY CELL TYPE, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY CARDIOMYOCYTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY CARDIOMYOCYTES, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY NEURONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY NEURONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY PANCREATIC BETA CELLS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY PANCREATIC BETA CELLS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY CELL THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY DISEASE MODELING, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY DISEASE MODELING, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY REPROGRAMMING METHOD, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY REPROGRAMMING METHOD, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY SMALL MOLECULES, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY TRANSDUCTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY TRANSDUCTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY NON-VIRAL VECTOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY NON-VIRAL VECTOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY TRANSDUCTION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY TRANSDUCTION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY TRANSFECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY TRANSFECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY ELECTROPORATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY ELECTROPORATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY LIPID BASED, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY LIPID BASED, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY TRANSFECTION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY TRANSFECTION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY BIOTECH PHARMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY BIOTECH PHARMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY CROS, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL CELL REPROGRAMMING MARKET SIZE, BY CROS, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. AMERICAS CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 66. AMERICAS CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS CELL REPROGRAMMING MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS CELL REPROGRAMMING MARKET SIZE, BY CELL TYPE, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS CELL REPROGRAMMING MARKET SIZE, BY REPROGRAMMING METHOD, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS CELL REPROGRAMMING MARKET SIZE, BY REPROGRAMMING METHOD, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS CELL REPROGRAMMING MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS CELL REPROGRAMMING MARKET SIZE, BY SMALL MOLECULES, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS CELL REPROGRAMMING MARKET SIZE, BY TRANSDUCTION, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS CELL REPROGRAMMING MARKET SIZE, BY TRANSDUCTION, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS CELL REPROGRAMMING MARKET SIZE, BY TRANSFECTION, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS CELL REPROGRAMMING MARKET SIZE, BY TRANSFECTION, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS CELL REPROGRAMMING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS CELL REPROGRAMMING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS CELL REPROGRAMMING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS CELL REPROGRAMMING MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 83. UNITED STATES CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 84. UNITED STATES CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 85. UNITED STATES CELL REPROGRAMMING MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
TABLE 86. UNITED STATES CELL REPROGRAMMING MARKET SIZE, BY CELL TYPE, 2025-2030 (USD MILLION)
TABLE 87. UNITED STATES CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 88. UNITED STATES CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES CELL REPROGRAMMING MARKET SIZE, BY REPROGRAMMING METHOD, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES CELL REPROGRAMMING MARKET SIZE, BY REPROGRAMMING METHOD, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES CELL REPROGRAMMING MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES CELL REPROGRAMMING MARKET SIZE, BY SMALL MOLECULES, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES CELL REPROGRAMMING MARKET SIZE, BY TRANSDUCTION, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES CELL REPROGRAMMING MARKET SIZE, BY TRANSDUCTION, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES CELL REPROGRAMMING MARKET SIZE, BY TRANSFECTION, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES CELL REPROGRAMMING MARKET SIZE, BY TRANSFECTION, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES CELL REPROGRAMMING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES CELL REPROGRAMMING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES CELL REPROGRAMMING MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES CELL REPROGRAMMING MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 101. CANADA CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 102. CANADA CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 103. CANADA CELL REPROGRAMMING MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
TABLE 104. CANADA CELL REPROGRAMMING MARKET SIZE, BY CELL TYPE, 2025-2030 (USD MILLION)
TABLE 105. CANADA CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 106. CANADA CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 107. CANADA CELL REPROGRAMMING MARKET SIZE, BY REPROGRAMMING METHOD, 2018-2024 (USD MILLION)
TABLE 108. CANADA CELL REPROGRAMMING MARKET SIZE, BY REPROGRAMMING METHOD, 2025-2030 (USD MILLION)
TABLE 109. CANADA CELL REPROGRAMMING MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
TABLE 110. CANADA CELL REPROGRAMMING MARKET SIZE, BY SMALL MOLECULES, 2025-2030 (USD MILLION)
TABLE 111. CANADA CELL REPROGRAMMING MARKET SIZE, BY TRANSDUCTION, 2018-2024 (USD MILLION)
TABLE 112. CANADA CELL REPROGRAMMING MARKET SIZE, BY TRANSDUCTION, 2025-2030 (USD MILLION)
TABLE 113. CANADA CELL REPROGRAMMING MARKET SIZE, BY TRANSFECTION, 2018-2024 (USD MILLION)
TABLE 114. CANADA CELL REPROGRAMMING MARKET SIZE, BY TRANSFECTION, 2025-2030 (USD MILLION)
TABLE 115. CANADA CELL REPROGRAMMING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 116. CANADA CELL REPROGRAMMING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 117. MEXICO CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 118. MEXICO CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 119. MEXICO CELL REPROGRAMMING MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
TABLE 120. MEXICO CELL REPROGRAMMING MARKET SIZE, BY CELL TYPE, 2025-2030 (USD MILLION)
TABLE 121. MEXICO CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 122. MEXICO CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 123. MEXICO CELL REPROGRAMMING MARKET SIZE, BY REPROGRAMMING METHOD, 2018-2024 (USD MILLION)
TABLE 124. MEXICO CELL REPROGRAMMING MARKET SIZE, BY REPROGRAMMING METHOD, 2025-2030 (USD MILLION)
TABLE 125. MEXICO CELL REPROGRAMMING MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
TABLE 126. MEXICO CELL REPROGRAMMING MARKET SIZE, BY SMALL MOLECULES, 2025-2030 (USD MILLION)
TABLE 127. MEXICO CELL REPROGRAMMING MARKET SIZE, BY TRANSDUCTION, 2018-2024 (USD MILLION)
TABLE 128. MEXICO CELL REPROGRAMMING MARKET SIZE, BY TRANSDUCTION, 2025-2030 (USD MILLION)
TABLE 129. MEXICO CELL REPROGRAMMING MARKET SIZE, BY TRANSFECTION, 2018-2024 (USD MILLION)
TABLE 130. MEXICO CELL REPROGRAMMING MARKET SIZE, BY TRANSFECTION, 2025-2030 (USD MILLION)
TABLE 131. MEXICO CELL REPROGRAMMING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 132. MEXICO CELL REPROGRAMMING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 133. BRAZIL CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 134. BRAZIL CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 135. BRAZIL CELL REPROGRAMMING MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
TABLE 136. BRAZIL CELL REPROGRAMMING MARKET SIZE, BY CELL TYPE, 2025-2030 (USD MILLION)
TABLE 137. BRAZIL CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 138. BRAZIL CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 139. BRAZIL CELL REPROGRAMMING MARKET SIZE, BY REPROGRAMMING METHOD, 2018-2024 (USD MILLION)
TABLE 140. BRAZIL CELL REPROGRAMMING MARKET SIZE, BY REPROGRAMMING METHOD, 2025-2030 (USD MILLION)
TABLE 141. BRAZIL CELL REPROGRAMMING MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
TABLE 142. BRAZIL CELL REPROGRAMMING MARKET SIZE, BY SMALL MOLECULES, 2025-2030 (USD MILLION)
TABLE 143. BRAZIL CELL REPROGRAMMING MARKET SIZE, BY TRANSDUCTION, 2018-2024 (USD MILLION)
TABLE 144. BRAZIL CELL REPROGRAMMING MARKET SIZE, BY TRANSDUCTION, 2025-2030 (USD MILLION)
TABLE 145. BRAZIL CELL REPROGRAMMING MARKET SIZE, BY TRANSFECTION, 2018-2024 (USD MILLION)
TABLE 146. BRAZIL CELL REPROGRAMMING MARKET SIZE, BY TRANSFECTION, 2025-2030 (USD MILLION)
TABLE 147. BRAZIL CELL REPROGRAMMING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 148. BRAZIL CELL REPROGRAMMING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 149. ARGENTINA CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 150. ARGENTINA CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 151. ARGENTINA CELL REPROGRAMMING MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
TABLE 152. ARGENTINA CELL REPROGRAMMING MARKET SIZE, BY CELL TYPE, 2025-2030 (USD MILLION)
TABLE 153. ARGENTINA CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 154. ARGENTINA CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 155. ARGENTINA CELL REPROGRAMMING MARKET SIZE, BY REPROGRAMMING METHOD, 2018-2024 (USD MILLION)
TABLE 156. ARGENTINA CELL REPROGRAMMING MARKET SIZE, BY REPROGRAMMING METHOD, 2025-2030 (USD MILLION)
TABLE 157. ARGENTINA CELL REPROGRAMMING MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
TABLE 158. ARGENTINA CELL REPROGRAMMING MARKET SIZE, BY SMALL MOLECULES, 2025-2030 (USD MILLION)
TABLE 159. ARGENTINA CELL REPROGRAMMING MARKET SIZE, BY TRANSDUCTION, 2018-2024 (USD MILLION)
TABLE 160. ARGENTINA CELL REPROGRAMMING MARKET SIZE, BY TRANSDUCTION, 2025-2030 (USD MILLION)
TABLE 161. ARGENTINA CELL REPROGRAMMING MARKET SIZE, BY TRANSFECTION, 2018-2024 (USD MILLION)
TABLE 162. ARGENTINA CELL REPROGRAMMING MARKET SIZE, BY TRANSFECTION, 2025-2030 (USD MILLION)
TABLE 163. ARGENTINA CELL REPROGRAMMING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 164. ARGENTINA CELL REPROGRAMMING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 165. EUROPE, MIDDLE EAST & AFRICA CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 166. EUROPE, MIDDLE EAST & AFRICA CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA CELL REPROGRAMMING MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA CELL REPROGRAMMING MARKET SIZE, BY CELL TYPE, 2025-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA CELL REPROGRAMMING MARKET SIZE, BY REPROGRAMMING METHOD, 2018-2024 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA CELL REPROGRAMMING MARKET SIZE, BY REPROGRAMMING METHOD, 2025-2030 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA CELL REPROGRAMMING MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA CELL REPROGRAMMING MARKET SIZE, BY SMALL MOLECULES, 2025-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA CELL REPROGRAMMING MARKET SIZE, BY TRANSDUCTION, 2018-2024 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA CELL REPROGRAMMING MARKET SIZE, BY TRANSDUCTION, 2025-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA CELL REPROGRAMMING MARKET SIZE, BY TRANSFECTION, 2018-2024 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA CELL REPROGRAMMING MARKET SIZE, BY TRANSFECTION, 2025-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA CELL REPROGRAMMING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA CELL REPROGRAMMING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA CELL REPROGRAMMING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA CELL REPROGRAMMING MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 183. UNITED KINGDOM CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 184. UNITED KINGDOM CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 185. UNITED KINGDOM CELL REPROGRAMMING MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
TABLE 186. UNITED KINGDOM CELL REPROGRAMMING MARKET SIZE, BY CELL TYPE, 2025-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 188. UNITED KINGDOM CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM CELL REPROGRAMMING MARKET SIZE, BY REPROGRAMMING METHOD, 2018-2024 (USD MILLION)
TABLE 190. UNITED KINGDOM CELL REPROGRAMMING MARKET SIZE, BY REPROGRAMMING METHOD, 2025-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM CELL REPROGRAMMING MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
TABLE 192. UNITED KINGDOM CELL REPROGRAMMING MARKET SIZE, BY SMALL MOLECULES, 2025-2030 (USD MILLION)
TABLE 193. UNITED KINGDOM CELL REPROGRAMMING MARKET SIZE, BY TRANSDUCTION, 2018-2024 (USD MILLION)
TABLE 194. UNITED KINGDOM CELL REPROGRAMMING MARKET SIZE, BY TRANSDUCTION, 2025-2030 (USD MILLION)
TABLE 195. UNITED KINGDOM CELL REPROGRAMMING MARKET SIZE, BY TRANSFECTION, 2018-2024 (USD MILLION)
TABLE 196. UNITED KINGDOM CELL REPROGRAMMING MARKET SIZE, BY TRANSFECTION, 2025-2030 (USD MILLION)
TABLE 197. UNITED KINGDOM CELL REPROGRAMMING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 198. UNITED KINGDOM CELL REPROGRAMMING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 199. GERMANY CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 200. GERMANY CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 201. GERMANY CELL REPROGRAMMING MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
TABLE 202. GERMANY CELL REPROGRAMMING MARKET SIZE, BY CELL TYPE, 2025-2030 (USD MILLION)
TABLE 203. GERMANY CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 204. GERMANY CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 205. GERMANY CELL REPROGRAMMING MARKET SIZE, BY REPROGRAMMING METHOD, 2018-2024 (USD MILLION)
TABLE 206. GERMANY CELL REPROGRAMMING MARKET SIZE, BY REPROGRAMMING METHOD, 2025-2030 (USD MILLION)
TABLE 207. GERMANY CELL REPROGRAMMING MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
TABLE 208. GERMANY CELL REPROGRAMMING MARKET SIZE, BY SMALL MOLECULES, 2025-2030 (USD MILLION)
TABLE 209. GERMANY CELL REPROGRAMMING MARKET SIZE, BY TRANSDUCTION, 2018-2024 (USD MILLION)
TABLE 210. GERMANY CELL REPROGRAMMING MARKET SIZE, BY TRANSDUCTION, 2025-2030 (USD MILLION)
TABLE 211. GERMANY CELL REPROGRAMMING MARKET SIZE, BY TRANSFECTION, 2018-2024 (USD MILLION)
TABLE 212. GERMANY CELL REPROGRAMMING MARKET SIZE, BY TRANSFECTION, 2025-2030 (USD MILLION)
TABLE 213. GERMANY CELL REPROGRAMMING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 214. GERMANY CELL REPROGRAMMING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 215. FRANCE CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 216. FRANCE CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 217. FRANCE CELL REPROGRAMMING MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
TABLE 218. FRANCE CELL REPROGRAMMING MARKET SIZE, BY CELL TYPE, 2025-2030 (USD MILLION)
TABLE 219. FRANCE CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 220. FRANCE CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 221. FRANCE CELL REPROGRAMMING MARKET SIZE, BY REPROGRAMMING METHOD, 2018-2024 (USD MILLION)
TABLE 222. FRANCE CELL REPROGRAMMING MARKET SIZE, BY REPROGRAMMING METHOD, 2025-2030 (USD MILLION)
TABLE 223. FRANCE CELL REPROGRAMMING MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
TABLE 224. FRANCE CELL REPROGRAMMING MARKET SIZE, BY SMALL MOLECULES, 2025-2030 (USD MILLION)
TABLE 225. FRANCE CELL REPROGRAMMING MARKET SIZE, BY TRANSDUCTION, 2018-2024 (USD MILLION)
TABLE 226. FRANCE CELL REPROGRAMMING MARKET SIZE, BY TRANSDUCTION, 2025-2030 (USD MILLION)
TABLE 227. FRANCE CELL REPROGRAMMING MARKET SIZE, BY TRANSFECTION, 2018-2024 (USD MILLION)
TABLE 228. FRANCE CELL REPROGRAMMING MARKET SIZE, BY TRANSFECTION, 2025-2030 (USD MILLION)
TABLE 229. FRANCE CELL REPROGRAMMING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 230. FRANCE CELL REPROGRAMMING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 231. RUSSIA CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 232. RUSSIA CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 233. RUSSIA CELL REPROGRAMMING MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
TABLE 234. RUSSIA CELL REPROGRAMMING MARKET SIZE, BY CELL TYPE, 2025-2030 (USD MILLION)
TABLE 235. RUSSIA CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 236. RUSSIA CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 237. RUSSIA CELL REPROGRAMMING MARKET SIZE, BY REPROGRAMMING METHOD, 2018-2024 (USD MILLION)
TABLE 238. RUSSIA CELL REPROGRAMMING MARKET SIZE, BY REPROGRAMMING METHOD, 2025-2030 (USD MILLION)
TABLE 239. RUSSIA CELL REPROGRAMMING MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
TABLE 240. RUSSIA CELL REPROGRAMMING MARKET SIZE, BY SMALL MOLECULES, 2025-2030 (USD MILLION)
TABLE 241. RUSSIA CELL REPROGRAMMING MARKET SIZE, BY TRANSDUCTION, 2018-2024 (USD MILLION)
TABLE 242. RUSSIA CELL REPROGRAMMING MARKET SIZE, BY TRANSDUCTION, 2025-2030 (USD MILLION)
TABLE 243. RUSSIA CELL REPROGRAMMING MARKET SIZE, BY TRANSFECTION, 2018-2024 (USD MILLION)
TABLE 244. RUSSIA CELL REPROGRAMMING MARKET SIZE, BY TRANSFECTION, 2025-2030 (USD MILLION)
TABLE 245. RUSSIA CELL REPROGRAMMING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 246. RUSSIA CELL REPROGRAMMING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 247. ITALY CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 248. ITALY CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 249. ITALY CELL REPROGRAMMING MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
TABLE 250. ITALY CELL REPROGRAMMING MARKET SIZE, BY CELL TYPE, 2025-2030 (USD MILLION)
TABLE 251. ITALY CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 252. ITALY CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 253. ITALY CELL REPROGRAMMING MARKET SIZE, BY REPROGRAMMING METHOD, 2018-2024 (USD MILLION)
TABLE 254. ITALY CELL REPROGRAMMING MARKET SIZE, BY REPROGRAMMING METHOD, 2025-2030 (USD MILLION)
TABLE 255. ITALY CELL REPROGRAMMING MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
TABLE 256. ITALY CELL REPROGRAMMING MARKET SIZE, BY SMALL MOLECULES, 2025-2030 (USD MILLION)
TABLE 257. ITALY CELL REPROGRAMMING MARKET SIZE, BY TRANSDUCTION, 2018-2024 (USD MILLION)
TABLE 258. ITALY CELL REPROGRAMMING MARKET SIZE, BY TRANSDUCTION, 2025-2030 (USD MILLION)
TABLE 259. ITALY CELL REPROGRAMMING MARKET SIZE, BY TRANSFECTION, 2018-2024 (USD MILLION)
TABLE 260. ITALY CELL REPROGRAMMING MARKET SIZE, BY TRANSFECTION, 2025-2030 (USD MILLION)
TABLE 261. ITALY CELL REPROGRAMMING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 262. ITALY CELL REPROGRAMMING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 263. SPAIN CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 264. SPAIN CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 265. SPAIN CELL REPROGRAMMING MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
TABLE 266. SPAIN CELL REPROGRAMMING MARKET SIZE, BY CELL TYPE, 2025-2030 (USD MILLION)
TABLE 267. SPAIN CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 268. SPAIN CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 269. SPAIN CELL REPROGRAMMING MARKET SIZE, BY REPROGRAMMING METHOD, 2018-2024 (USD MILLION)
TABLE 270. SPAIN CELL REPROGRAMMING MARKET SIZE, BY REPROGRAMMING METHOD, 2025-2030 (USD MILLION)
TABLE 271. SPAIN CELL REPROGRAMMING MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
TABLE 272. SPAIN CELL REPROGRAMMING MARKET SIZE, BY SMALL MOLECULES, 2025-2030 (USD MILLION)
TABLE 273. SPAIN CELL REPROGRAMMING MARKET SIZE, BY TRANSDUCTION, 2018-2024 (USD MILLION)
TABLE 274. SPAIN CELL REPROGRAMMING MARKET SIZE, BY TRANSDUCTION, 2025-2030 (USD MILLION)
TABLE 275. SPAIN CELL REPROGRAMMING MARKET SIZE, BY TRANSFECTION, 2018-2024 (USD MILLION)
TABLE 276. SPAIN CELL REPROGRAMMING MARKET SIZE, BY TRANSFECTION, 2025-2030 (USD MILLION)
TABLE 277. SPAIN CELL REPROGRAMMING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 278. SPAIN CELL REPROGRAMMING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 279. UNITED ARAB EMIRATES CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 280. UNITED ARAB EMIRATES CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 281. UNITED ARAB EMIRATES CELL REPROGRAMMING MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
TABLE 282. UNITED ARAB EMIRATES CELL REPROGRAMMING MARKET SIZE, BY CELL TYPE, 2025-2030 (USD MILLION)
TABLE 283. UNITED ARAB EMIRATES CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 284. UNITED ARAB EMIRATES CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 285. UNITED ARAB EMIRATES CELL REPROGRAMMING MARKET SIZE, BY REPROGRAMMING METHOD, 2018-2024 (USD MILLION)
TABLE 286. UNITED ARAB EMIRATES CELL REPROGRAMMING MARKET SIZE, BY REPROGRAMMING METHOD, 2025-2030 (USD MILLION)
TABLE 287. UNITED ARAB EMIRATES CELL REPROGRAMMING MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
TABLE 288. UNITED ARAB EMIRATES CELL REPROGRAMMING MARKET SIZE, BY SMALL MOLECULES, 2025-2030 (USD MILLION)
TABLE 289. UNITED ARAB EMIRATES CELL REPROGRAMMING MARKET SIZE, BY TRANSDUCTION, 2018-2024 (USD MILLION)
TABLE 290. UNITED ARAB EMIRATES CELL REPROGRAMMING MARKET SIZE, BY TRANSDUCTION, 2025-2030 (USD MILLION)
TABLE 291. UNITED ARAB EMIRATES CELL REPROGRAMMING MARKET SIZE, BY TRANSFECTION, 2018-2024 (USD MILLION)
TABLE 292. UNITED ARAB EMIRATES CELL REPROGRAMMING MARKET SIZE, BY TRANSFECTION, 2025-2030 (USD MILLION)
TABLE 293. UNITED ARAB EMIRATES CELL REPROGRAMMING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 294. UNITED ARAB EMIRATES CELL REPROGRAMMING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 295. SAUDI ARABIA CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 296. SAUDI ARABIA CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 297. SAUDI ARABIA CELL REPROGRAMMING MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
TABLE 298. SAUDI ARABIA CELL REPROGRAMMING MARKET SIZE, BY CELL TYPE, 2025-2030 (USD MILLION)
TABLE 299. SAUDI ARABIA CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 300. SAUDI ARABIA CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 301. SAUDI ARABIA CELL REPROGRAMMING MARKET SIZE, BY REPROGRAMMING METHOD, 2018-2024 (USD MILLION)
TABLE 302. SAUDI ARABIA CELL REPROGRAMMING MARKET SIZE, BY REPROGRAMMING METHOD, 2025-2030 (USD MILLION)
TABLE 303. SAUDI ARABIA CELL REPROGRAMMING MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
TABLE 304. SAUDI ARABIA CELL REPROGRAMMING MARKET SIZE, BY SMALL MOLECULES, 2025-2030 (USD MILLION)
TABLE 305. SAUDI ARABIA CELL REPROGRAMMING MARKET SIZE, BY TRANSDUCTION, 2018-2024 (USD MILLION)
TABLE 306. SAUDI ARABIA CELL REPROGRAMMING MARKET SIZE, BY TRANSDUCTION, 2025-2030 (USD MILLION)
TABLE 307. SAUDI ARABIA CELL REPROGRAMMING MARKET SIZE, BY TRANSFECTION, 2018-2024 (USD MILLION)
TABLE 308. SAUDI ARABIA CELL REPROGRAMMING MARKET SIZE, BY TRANSFECTION, 2025-2030 (USD MILLION)
TABLE 309. SAUDI ARABIA CELL REPROGRAMMING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 310. SAUDI ARABIA CELL REPROGRAMMING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 311. SOUTH AFRICA CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 312. SOUTH AFRICA CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 313. SOUTH AFRICA CELL REPROGRAMMING MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
TABLE 314. SOUTH AFRICA CELL REPROGRAMMING MARKET SIZE, BY CELL TYPE, 2025-2030 (USD MILLION)
TABLE 315. SOUTH AFRICA CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 316. SOUTH AFRICA CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 317. SOUTH AFRICA CELL REPROGRAMMING MARKET SIZE, BY REPROGRAMMING METHOD, 2018-2024 (USD MILLION)
TABLE 318. SOUTH AFRICA CELL REPROGRAMMING MARKET SIZE, BY REPROGRAMMING METHOD, 2025-2030 (USD MILLION)
TABLE 319. SOUTH AFRICA CELL REPROGRAMMING MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
TABLE 320. SOUTH AFRICA CELL REPROGRAMMING MARKET SIZE, BY SMALL MOLECULES, 2025-2030 (USD MILLION)
TABLE 321. SOUTH AFRICA CELL REPROGRAMMING MARKET SIZE, BY TRANSDUCTION, 2018-2024 (USD MILLION)
TABLE 322. SOUTH AFRICA CELL REPROGRAMMING MARKET SIZE, BY TRANSDUCTION, 2025-2030 (USD MILLION)
TABLE 323. SOUTH AFRICA CELL REPROGRAMMING MARKET SIZE, BY TRANSFECTION, 2018-2024 (USD MILLION)
TABLE 324. SOUTH AFRICA CELL REPROGRAMMING MARKET SIZE, BY TRANSFECTION, 2025-2030 (USD MILLION)
TABLE 325. SOUTH AFRICA CELL REPROGRAMMING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 326. SOUTH AFRICA CELL REPROGRAMMING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 327. DENMARK CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 328. DENMARK CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 329. DENMARK CELL REPROGRAMMING MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
TABLE 330. DENMARK CELL REPROGRAMMING MARKET SIZE, BY CELL TYPE, 2025-2030 (USD MILLION)
TABLE 331. DENMARK CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 332. DENMARK CELL REPROGRAMMING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 333. DENMARK CELL REPROGRAMMING MARKET SIZE, BY REPROGRAMMING METHOD, 2018-2024 (USD MILLION)
TABLE 334. DENMARK CELL REPROGRAMMING MARKET SIZE, BY REPROGRAMMING METHOD, 2025-2030 (USD MILLION)
TABLE 335. DENMARK CELL REPROGRAMMING MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
TABLE 336. DENMARK CELL REPROGRAMMING MARKET SIZE, BY SMALL MOLECULES, 2025-2030 (USD MILLION)
TABLE 337. DENMARK CELL REPROGRAMMING MARKET SIZE, BY TRANSDUCTION, 2018-2024 (USD MILLION)
TABLE 338. DENMARK CELL REPROGRAMMING MARKET SIZE, BY TRANSDUCTION, 2025-2030 (USD MILLION)
TABLE 339. DENMARK CELL REPROGRAMMING MARKET SIZE, BY TRANSFECTION, 2018-2024 (USD MILLION)
TABLE 340. DENMARK CELL REPROGRAMMING MARKET SIZE, BY TRANSFECTION, 2025-2030 (USD MILLION)
TABLE 341. DENMARK CELL REPROGRAMMING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 342. DENMARK CELL REPROGRAMMING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 343. NETHERLANDS CELL REPROGRAMMING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 344. NETHERLANDS CELL REPROGRAMMING MARKET SIZE, BY TEC

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Cell Reprogramming market report include:
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Lonza Group AG
  • Danaher Corporation
  • STEMCELL Technologies Inc.
  • Takara Bio Inc.
  • FUJIFILM Cellular Dynamics Inc.
  • Miltenyi Biotec GmbH
  • Bio-Techne Corporation
  • ReproCELL, Inc.

Table Information

Report AttributeDetails
No. of Pages193
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 458.87 Million
Forecasted Market Value ( USD ) by 2030 $ 760.75 Million
Compound Annual Growth Rate10.6%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Cell Reprogramming Market Size, Share & Trends Analysis Report by Technology (Sendai Virus-based Reprogramming, MRNA Reprogramming, Episomal Reprogramming), Application (Research, Therapeutic), End-use, Region, with Growth Forecasts, 2025-2030 - Product Image

Cell Reprogramming Market Size, Share & Trends Analysis Report by Technology (Sendai Virus-based Reprogramming, MRNA Reprogramming, Episomal Reprogramming), Application (Research, Therapeutic), End-use, Region, with Growth Forecasts, 2025-2030

  • Report
  • 120 Pages
  • Global
From
Cell Reprogramming - Global Strategic Business Report - Product Image

Cell Reprogramming - Global Strategic Business Report

  • Report
  • 369 Pages
  • Global
From
Cell Reprogramming Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Cell Reprogramming Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 182 Pages
  • Global
From
2025 Global Forecast for Cell Reprogramming (2026-2031 Outlook)-High Tech Outlook Report - Product Image

2025 Global Forecast for Cell Reprogramming (2026-2031 Outlook)-High Tech Outlook Report

  • Report
  • 132 Pages
  • Global
From
Chemical Biology in Regenerative Medicine. Bridging Stem Cells and Future Therapies. Edition No. 1 - Product Image

Chemical Biology in Regenerative Medicine. Bridging Stem Cells and Future Therapies. Edition No. 1

  • Book
  • 240 Pages

About the Market

Cell reprogramming is a biotechnology process that involves the conversion of a cell from one type to another. It is used to create induced pluripotent stem cells (iPSCs) from adult cells, which can then be used to study diseases, develop new treatments, and create personalized medicine. Cell reprogramming is also used to create cell models of diseases, which can be used to study the underlying mechanisms of the disease and develop new therapies. Additionally, cell reprogramming can be used to create cell-based therapies, such as gene therapy, which can be used to treat genetic diseases. Cell reprogramming is a rapidly growing field, with many companies investing in the technology. Some of the companies in the market include Ginkgo Bioworks, Cellular Dynamics International, Fate Therapeutics, and Pluristem Therapeutics. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.